NAL 0.00% 0.6¢ norwood abbey limited

needleless breakthrough

  1. 5,447 Posts.
    NORWOOD ABBEY LIMITED 2002-11-26 ASX-SIGNAL-G

    HOMEX - Melbourne

    +++++++++++++++++++++++++
    KEY POINTS:

    * Needle-less injection device created
    * Overcomes concerns of existing needle-less injections
    * Low per procedure cost
    * Provisional patent applications lodged
    * Shape memory alloy technology licensed from McGill University
    * Discussions with potential commercial partners have commenced

    Medical technologies group Norwood Abbey Ltd (ASX:NAL) advises that
    in the course of work done under its research agreement with
    Massachusetts Institute of Technology ("MIT"), a unique needle-less
    injection device has been created. Because this device emerged during
    other research being conducted by MIT, Norwood has not incurred any
    additional development costs.

    The needle-less injection device was developed at the MIT
    BioInstrumentation Laboratory, under the direction of Professor Ian
    Hunter. It is expected to be suitable for use in human and veterinary
    applications.

    Under this injection system, the drug is delivered through the skin
    using a small hand-held device. The system uses a novel, patented and
    extremely fast and powerful contractile fibre-activated pump that
    fires the drug at the skin with sufficient velocity to penetrate
    without the use of needles. The drug vial is designed as a single-use
    disposable, easily inserted into the portable applicator device.

    The key idea behind the technology is the use of very fast
    contracting shape memory alloy fibres.

    The shape memory alloy fibres (typically an alloy of nickel and
    titanium) are activated using a brief electrical pulse whose
    initiation, duration and general shape are controlled by an embedded
    computer. These fibres can be designed to contract and produce
    gigantic forces.

    The drug in the device is contained within a miniature cylinder and
    piston (like a very small syringe). The fibres are attached to the
    piston and when they contract they cause the piston to exert high
    pressure on the drug. This pressure then causes the drug to be fired
    out through a small orifice at the other end of the cylinder. Bench
    level prototype devices have been built. It is planned that devices
    will be designed for both single shot and multiple shot
    administration. A small, embedded processor, and associated circuitry
    to control the injector, has also been developed and programmed.
    Preliminary laboratory tests have achieved delivery of a drug into
    isolated pig skin.

    Norwood has also entered into a licensing agreement with McGill
    University in relation to the underlying shape memory alloy
    technology. This technology was invented by Professor Hunter et al
    during his time at McGill University. The Company has lodged
    provisional patent applications covering key aspects this technology.

    Having completed the intellectual property protection, Norwood has
    commenced initial discussions with potential commercial partners for
    the needle-less injection device.

    "We are very pleased to be involved in the development and
    commercialization of such an important medical device," commented
    Peter J Hansen, Chairman of Norwood Abbey. "Needle-less injection
    will eliminated the dangers to health care workers caused by needle
    stick injuries. It is estimated that more than one million sharp
    injuries occur every year world wide, by objects such as needles,
    blades, lancets, knives and any other sharp items."

    The Company further noted that as a result of the widely-publicised
    risks of needle-stick injury associated with conventional injections,
    legislation has recently been passed in the United States which
    requires employers to provide safety features in sharp medical
    devices.

    Key attractions of this needle-less injection system are:

    * It is expected to be an extremely cheap means of administering
    injections
    * It is a simple technical concept providing easy manufacture
    * High per procedure profit margins expected
    * It is safe,
    * It is silent
    * It allows delivery of varying doses and in a controlled manner
    * It overcomes key concerns with existing needle-less injection
    devices (see below)

    Existing needless injection devices typically use either compressed
    gas or, via a fast chemical reaction, produce a gas (similar to an
    automotive air bag) to force a fixed quantity of drug out through a
    small orifice at a velocity that is high enough to penetrate skin.
    Existing devices have a number of problems:

    1. The per procedure cost is high

    2. They involve what is in essence a miniature explosion and are
    consequently very noisy (similar to an air rifle shot). This causes
    many people (especially children) to find the procedure aversive.

    3. The dose cannot be varied (eg according to body weight, age, sex,
    etc).

    4. They are not controllable in the sense that a computer (rather
    than a trigger) can control delivery characteristics. For example the
    force of penetration is fixed and so when used with people with
    compliant skin (children, old ladies) widely varying penetration
    depths will result.

    The new device has been designed to overcome these problems and
    limitations.

    Norwood's portfolio of drug-delivery devices now comprises:

    * Laser assisted device commercial partner in place;
    * Microneedle device prototype development completed;
    * Needle-less injection bench working prototype produced;
    * Gene transfer program

    To learn more about the Company, visit www.norwoodabbey.com

    For further information about the project contact:

    Australia Company Contacts US Investor Contacts
    Peter Hansen, EXECUTIVE CHAIRMAN Lippert Heilshorn & Assoc
    613-9782-7333 Kim Sutton Golodetz
    [email protected]
    Bernie Romanin, DIRECTOR OF MARKETING 212-838-3777
    613-9782-7333 Bruce Voss
    310-691-7100
    [email protected]
    www.lhai.com
 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.